Assessment of Anti Glutamate receptor (GLUR1 Ab) and Interleukin-6 Levels in Patients with Epilepsy in Al-Diwaniyah Governorate
DOI:
https://doi.org/10.46649/v3c7yb08Keywords:
Epilepsy, Anti-Glutamate Receptor 1, IL-6Abstract
Epilepsy is a chronic neurological condition characterized by recurrent and unprovoked seizures resulting from abnormal electrical activity of the brain. All of them were evaluated within this study in relation to blood IL-6, and anti-glutamate receptor 1 antibody (GluR1 Ab) levels from epileptic patients and controls. A case-control study design was used, the study included all patient referred to the Neurology Center of Al-Diwaniyah Teaching Hospital in Al-Diwaniyah Governorate from a period between November 2025 and March 2026. Fifty controls and fifty epileptic patients were included in the study. Outcomes: All participants had venous blood samples taken. GluR1 Ab and IL-6 were detected in serum with enzyme-linked immunosorbent assay (ELISA). SPSS version 26 was used for indicating the results and P < 0.05 was considered statistically significant. According to the findings, epilepsy patients had a substantially higher mean blood GLUR1 Ab level than controls (35.29 ± 6.75 vs. 12.17 ± 3.8, P = 0.001). Similarly, patients had substantially higher blood IL-6 levels than controls (252.17 ± 18.61 vs. 175.01 ± 5.69, P < 0.001). In conclusion, individuals with epilepsy have significantly higher levels of both GLUR1 Ab and IL-6, indicating that the immune and inflammatory systems are involved in the disease. Among the markers examined, GLUR1 Ab outperformed IL-6 in terms of discriminatory performance and could be a more useful biomarker for epilepsy.
Published
Issue
Section
License
The Corresponding Author, with the consent of all coauthors, hereby transfers to the FJHMS the copyright ownership in referenced Article, including all versions in any format now known or the hereafter developed. If the Article is not accepted by FJHMS or withdrawn prior to acceptance, this transfer will be null and void.
In order for your article to be distributed as widely as possible your grant the FJHMS an exclusive right to:
- Publish, reproduce, distribute, display, and store the Article in all forms, formats, and media known or later developed (including without limitation in print, digital, and electronic form) throughout the world;
- Translate the Article into other languages, create adaptations, summaries or extracts of the Article or other derivative works based on the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, and derivative works;
- License others to do any or all of the above
All accepted Articles become the property of FJHMS and may not be published elsewhere without written permission of the FJHMS
